Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • Subscribe to Print Magazine
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

NewCardio to Present Results of QTinno Performance on Cardiac Safety Research Consortium Blinded ‘Testing’ Dataset

November 9, 2010 By Bio-Medicine.Org

SANTA CLARA, Calif., Nov. 9, 2010 /PRNewswire-FirstCall/ —
NewCardio, Inc. (OTC Bulletin Board:
NWCI
), a cardiovascular diagnostic solutions developer,
announced today that Dr. Samuel George, NewCardio’s Senior Medical
Advisor, will present the results of QTinno performance on a
blinded “testing” dataset, conducted independently by the Cardiac
Safety Research Consortium (CSRC), at the CSRC’s Annual Meeting, to
be held on December 9, 2010, at the headquarters of the Food and
Drug Administration (FDA) in Silver Spring, MD.  

At the meeting, Dr. George will present results of a blinded
validation study in which CSRC-affiliated investigators
independently evaluated the accuracy and precision of fully
automated QTinno measurements in 11,672 electrocardiograms (ECGs)
from the moxifloxacin and placebo arms of a recent Thorough QT
Study (TQTS). In the study, the CSRC investigators made detailed
comparisons of QTinno measurements to those originally submitted by
the drug sponsor, with the primary comparators of accurate
detection of the moxifloxacin effect on QT intervals.

The CSRC makes this blinded TQTS “testing” dataset available to
automated cardiac safety technology solution providers, with the
conditions that the blinded analysis is conducted independently by
the CSRC without any company involvement, and that any (either
favorable or unfavorable) results obtained will be made public.
NewCardio is the first company which has agreed to these conditions
and completed the evaluation.

Dr. Ihor Gussak, NewCardio’s Chief Medical Officer, commented,
“We are very proud to be the first  automated cardiac safety
solution to accept the rules of engagement defined by the CSRC for
evaluating the performance of our automated solution, QTinno,
utilizing the blinded CSRC ‘testing’ dataset. Our willingness to
enter into this very important and strictly regulated
validatio

‘/>”/>

SOURCE

Related Articles Read More >

Prix Galien USA 2022 nominees
The 24 best medical device innovations of 2022
A portrait of Ellen Roche, MIT School of Engineering associate professor
New implant design prevents scar tissue without drugs, MIT says
UMN artificial blood vessel clinical trial
Minnesota researchers awarded $3.7M grant for artificial, bioengineered blood vessel clinical trial
CeQur Simplicity
CeQur is launching a discreet, convenient ‘wearable insulin pen’

DeviceTalks Weekly.

August 12, 2022
DTW – Medtronic’s Mauri brings years of patient care to top clinical, regulatory, scientific post
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech100 Index
  • Medical Tubing + Extrusion
  • Medical Design Sourcing
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media LLC. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • Subscribe to Print Magazine
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech